Best's Review Looks Ahead at New Year Fraught With Inflation and Other Challenges
The December issue ofBest's Review examines issues that insurers are preparing for in 2023, with inflation as one of their top concerns:
In "MassMutual Prepares for the Worst Amid 2023 Warning Signs," Massachusetts Mutual Chairman and CEO Roger Crandall discusses the company's core strengths and how he aims to be flexible in the face of rising interest rates and shifting market demands.
Beginning in January, Best's Review's online magazine will move to a new, interactive format.
Best's Review is AM Best's monthly insurance magazine, covering emerging issues and trends and evaluating their impact on the marketplace. Access to the complete content of Best's Review is available here.
AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpointsVaccine candidate based on CureVac's proprietary second-generation mRNA backboneGSK...
Focused on Return to Profitability: 18.3% reduction in net loss to $6.8 million in the first nine months of 2024, down from $8.3 million in the same period of 2023; achieved 50.6% improvement over 2022, demonstrating strong commitment to reducing...
Signet Jewelers Limited ("Signet" or the "Company") , the world's largest retailer of diamond jewelry, today announced its results for the 13 weeks ended August 3, 2024 ("second quarter Fiscal 2025").
"I'd like to thank our Signet team for...
MYT Netherlands Parent B.V. ("Mytheresa" or the "Company") today announced financial results for its fourth quarter and full fiscal year 2024 ended June 30, 2024. The luxury multi-brand digital platform reported strong financial performance for the...
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive Phase 3 results for its RSV vaccine for high-risk...